BYM338

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary Disease (COPD) With CachexiaMechanical VentilationSkeletal MuscleSporadic Inclusion Body Myositis

Phase 2

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

CompletedNCT01423110

Novartis PharmaceuticalsSporadic Inclusion Body Myositis

Start: 2011-08-31End: 2012-05-31Updated: 2020-12-17

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

CompletedNCT01601600

Novartis PharmaceuticalsSkeletal Muscle

Start: 2012-01-31End: 2013-12-31Updated: 2020-12-17

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

CompletedNCT01669174

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD) With Cachexia

Start: 2012-09-30End: 2014-12-31Updated: 2016-05-03

Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients

WithdrawnNCT01868685

Novartis PharmaceuticalsMechanical Ventilation

Start: 2014-04-30End: 2015-01-31Updated: 2015-01-07

Related Papers

Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial

American Journal of Respiratory and Critical Care Medicine2018-08-1095 citations